2. Nucleic acids from uridina, including the therapeutically effective amount of components of these nucleic acid derivatives, and the method of using these nucleic acid derivatives or components to treat the disorder of parasites (such as analgesics)；For instanceNeurological disorders, including neurodegenerative disordersParkinson's disease and traumatic SNC injury, pain, Down's syndrome (SD),Glaucoma and inflammation. 1. Characteristic 1: a pharmaceutical component composed of a formula compound (1)；Or its salt, wherein: A is an aromatic or non aromatic ring of 3 to 10 members, with up to 5 heteroatoms independently selected from n, O, s, so or so or so 832222,3. Aromatic or non aromatic rings are independently and selectively replaced by one or more r8311；X selected from: - H, - C (o) r83099；-C (O) OR y -P (O) (OR)Preferably - H, - C (o) r83090；Y is an independent C₁₋₅ link or aliphatic group and optionally substituted with one or more R⁴；Z and W are respectively selected between = O, = s, = n (r83099) and = nor83099；R1 is selected from: - H, halogen, - or83099；-Cn, -CF₃；-Lcf83223 and a group of liquefiable substances c83318326 were selectively replaced by one or more r831181；R2 and R3 were selected from - or83099, respectively；-SR83099；-8309； 8310；-OC (O) R-OC (O) NR R y -OC (O) OREach substance in r830808 is selected independently from halogen to or83099；-No.8322；-Cn, -CF₃；-OCF8323,-R83099,1,2-methylenedioxy, 1,2-ethyldioxy-n (r83099) c83222；-SR83099；-Sor83099,-SO₂R⁵,-SO N (R)-SO₃R⁵,-C (O) R-C (O) C (O) R-C (O) CH C (O) R-C (S) R-C (S) OR-C (O) OR-C (O) C (O) OR-C (O) C (O) N (R)-OC (O) R-C (O) N (R)-OC (O) N (R)-C (S) N (R)- (CH) NHC (O) R-N (R) N (R) COR-N (R) N (R) C (O) OR-N (R) N (R) CON (R)-N (R) SO R-N (R) SO N (R)-N (R) C (O) OR-N (R) C (O) R-N (R) C (S) R-N (R) C (O) N (R)-N (R) C (S) N (R)-N (COR) COR-N (OR) R-C (3DNH) N (R)-C (O) N (OR) R-C (3DNOR) R-OP (O) (OR)-P (O) (R)-P (O) (OR) o -P (O) (H) (OR)Each of r83099 appears from H -,alif tico C -C₃₋₁₀
